Search for:
Anti-Corruption

Italy: The Medicines Agency’s Report on pharmaceutical expenditure in 2020

By and 1 Min Read

In brief

With a Report published on 21 April 2021, the Italian Medicines Agency (AIFA) made available the preliminary data relating to the Monitoring of the National and Regional Pharmaceutical Expenditure for the year 2020.

According to the Report, during that period the total national expenditure, including both the pharmaceutical expenditure for direct purchases and the territorial expenditure, amounted to EUR 18,890.3 million, showing an increase of approximately EUR 200 million compared to the previous year and a departure from the total resources of approximately EUR 1,134.2 million.

Moreover, data, which are in line with the growth trend observed over recent years, show that the pharmaceutical expenditure for direct purchases exceeded the annual expenditure ceiling (equal to EUR 2,700 million), whilst territorial expenditure stayed below the ceiling of EUR 1,565 million.

Categories:
Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.

Related Posts

Write A Comment